<DOC>
	<DOCNO>NCT01942915</DOCNO>
	<brief_summary>This study evaluate safety efficacy umbilical cord blood mononuclear cell transplantation liver cirrhosis patient .</brief_summary>
	<brief_title>Umbilical Cord Blood Mononuclear Cells Therapy Liver Cirrhosis</brief_title>
	<detailed_description>Decompensated liver cirrhosis ( LC ) , life-threatening complication chronic liver disease , one major indication liver transplantation . Recently , umbilical cord blood mononuclear cell transfusion show lead regression liver fibrosis animal model . The investigator thus investigate safety therapy life sign like temperature , pulse , blood pressure , incidence hepatocellular carcinoma mortality . And efficacy evaluate measurement alanine aminotransferase ( ALT ) , glutamic oxaloacetic transaminase ( AST ) , total bilirubin ( TBIL ) , direct bilirubin ( DBIL ) , albumin ( ALB ) , cholinesterase ( CHE ) , prothrombin time ( PT ) child-pugh score .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Patients hepatocirrhosis : accord standard child pugh , liver function achieve class A B patient , Including C class patient achieve B class treatment 1 . Patients C class childpugh score 2 . Patients acute phase severe hepatitis 3 . Patients diagnose cancer liver 4 . Patients severe cardiopulmonary cerebral disease , failure state 5 . Patients Highly allergic constitution 6 . Patients moderately severe mental disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>